Related Experiment Videos
Pars plana vitrectomy for refractory diabetic macular edema
Ruben Grigorian1, Neelakshi Bhagat, Paolo Lanzetta
1Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark 01701-1709, USA.
Seminars in Ophthalmology
|October 30, 2004
Summary
Pars plana vitrectomy (PPV) offers a beneficial treatment option for persistent diabetic macular edema (DME) unresponsive to other therapies. This surgical approach demonstrates significant improvements in vision and reduction in retinal edema for many patients.
Area of Science:
- Ophthalmology
- Retinal Surgery
Background:
- Diabetic macular edema (DME) is a leading cause of vision loss in diabetic patients.
- Refractory DME often requires advanced treatment strategies beyond conventional therapies like laser photocoagulation or steroid injections.
Purpose of the Study:
- To evaluate the efficacy and outcomes of pars plana vitrectomy (PPV) for diabetic macular edema (DME) that has not responded to standard treatments.
- To review the anatomical and functional results following PPV in refractory DME cases.
Main Methods:
- A comprehensive literature review of peer-reviewed scientific articles was conducted.
- Medline database was utilized to identify relevant studies on pars plana vitrectomy for diabetic macular edema.
Main Results:
- Pars plana vitrectomy (PPV), with or without internal limiting membrane (ILM) peeling, shows promise for DME resistant to laser or steroid treatments.
- Studies report visual improvement in 40-90% of patients and edema reduction in 70-100%.
- Potential complications include retinal breaks (5-20%), detachment (1-2%), macular holes (2%), and cataract development (10-60%).
Conclusions:
- Pars plana vitrectomy (PPV) is an effective surgical intervention for diabetic macular edema (DME) refractory to conventional therapies.
- The procedure can lead to significant visual and anatomical improvements, though potential complications must be considered.